These data indicate a paradoxical role for IL-33/ST2 signaling in GVHD, whereby early treatment of IL-33 downregulates inflammation in the GI tract, whereas administration of IL-33 is proinflammatory once disease has been established. Here, IL33 is linked to graft versus host disease.